Positron consolidates radiopharma, radioisotope facilities
Positron has consolidated the operations of its radiopharmaceutical and radioisotope businesses, some of which were located at its Crown Point, Ind., facility to its Lubbock, Texas site.
With the acquisition of Manhattan Isotope Technology (MIT), Positron gained the radioactive materials facilities to manage all of the company's radiopharmaceutical and radioisotope development, production, processing and distribution. Since the acquisition of MIT earlier this year, Positron said it has made developments in the production requirements of PET radiopharmaceutical products, making the integration of production and facilities to the Lubbock facilities possible. MIT possesses the proper licenses, staff, procedures and quality systems for Positron's pharmaceutical products.
The transfer of all records, systems and equipment was completed in late July. The production of Indium Oxyquinoline will resume upon the modification of the company's current Texas radiation license to include Indium Oxine, with expected approval in August, according to Positron.
By locating all radioactive production to a single facility, Positron hopes to simplify and improve regulatory compliance, radiation safety and quality procedures associated with the production of radioisotopes and radiopharmaceuticals.
Jason Kitten, MIT's president, said that MIT "will continue with the production capabilities developed at Crown Point with indium and its target material cadmium."
With the acquisition of Manhattan Isotope Technology (MIT), Positron gained the radioactive materials facilities to manage all of the company's radiopharmaceutical and radioisotope development, production, processing and distribution. Since the acquisition of MIT earlier this year, Positron said it has made developments in the production requirements of PET radiopharmaceutical products, making the integration of production and facilities to the Lubbock facilities possible. MIT possesses the proper licenses, staff, procedures and quality systems for Positron's pharmaceutical products.
The transfer of all records, systems and equipment was completed in late July. The production of Indium Oxyquinoline will resume upon the modification of the company's current Texas radiation license to include Indium Oxine, with expected approval in August, according to Positron.
By locating all radioactive production to a single facility, Positron hopes to simplify and improve regulatory compliance, radiation safety and quality procedures associated with the production of radioisotopes and radiopharmaceuticals.
Jason Kitten, MIT's president, said that MIT "will continue with the production capabilities developed at Crown Point with indium and its target material cadmium."